Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.11 Consensus PT from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $17.11.

A number of equities analysts have issued reports on the stock. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a report on Friday, August 30th. Needham & Company LLC reissued a “buy” rating and issued a $13.00 price target on shares of Alphatec in a report on Thursday, October 31st. Barclays boosted their price objective on Alphatec from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Thursday, October 31st. Finally, Lake Street Capital reduced their price target on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd.

Hedge Funds Weigh In On Alphatec

Institutional investors and hedge funds have recently bought and sold shares of the stock. Comerica Bank boosted its holdings in shares of Alphatec by 64.8% in the first quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock valued at $89,000 after acquiring an additional 2,534 shares in the last quarter. Van ECK Associates Corp lifted its position in Alphatec by 11.8% in the second quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock worth $128,000 after purchasing an additional 1,300 shares during the period. XTX Topco Ltd bought a new position in Alphatec during the 3rd quarter valued at $69,000. Cetera Advisors LLC boosted its stake in Alphatec by 15.6% during the 1st quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company’s stock valued at $175,000 after purchasing an additional 1,720 shares in the last quarter. Finally, Net Worth Advisory Group acquired a new position in shares of Alphatec during the 3rd quarter valued at $76,000. Institutional investors own 66.35% of the company’s stock.

Alphatec Stock Up 0.4 %

Shares of NASDAQ:ATEC opened at $9.65 on Wednesday. The company’s fifty day moving average is $7.72 and its two-hundred day moving average is $8.13. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec has a 1-year low of $4.88 and a 1-year high of $17.34. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -7.54 and a beta of 1.38.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.